BioSpace

AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.

By BioSpace

1 min read
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights